Pancreaticobiliary Neoplasm

Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. In a 54-year-old … (full text at CIViC)

PMID 31068372 · Jones et al., 2019 · Open in CIViC

In this phase II basket trial (TAPUR), response to olaparib treatment was examined in four cohorts with ATM mutations. In the pancreatic cancer cohort (25 evaluable patients) there was one PR and five… (full text at CIViC)

PMID 41538762 · Carrizosa et al., 2026 · Open in CIViC

A 77 year old man with metastatic pancreatic ductal adenocarcinoma with somatic ATM R2034Ter mutation received off label olaparib after prior chemotherap. His disease remained stable for 18 months.

PMID 40273902 · Vornhülz et al., 2025 · Open in CIViC

Absent expression of ATM, as assessed by IHC in 133 pancreatic ductal adenocarcinomas, was found to be associated with dismal prognosis (median survival, 9.6 months), whereas expression of ATM was ass… (full text at CIViC)

PMID 25423555 · Kamphues et al., 2015 · Open in CIViC

In a single patient with presumed cholangiocarcinoma a novel ATP1B1-NRG1 gene fusion was detected. Integrative genome analysis was used to assess the potential functional significance of the gene fusi… (full text at CIViC)

PMID 28950338 · Jones et al., 2017 · Open in CIViC

Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. A 59-year-old met… (full text at CIViC)

PMID 31068372 · Jones et al., 2019 · Open in CIViC

ATXN1L loss reduced sensitivity to trametinib in KRAS G12V pancreatic cancer cells (PATU8902, PATU8988T).

PMID 28178529 · Wang et al., 2017 · Open in CIViC

In an in vitro study, 537Mel, OV-90 and H2405 cell lines expressing BRAF N486_P490del mutation demonstrated resistance to vemurafenib treatment, compared to A-375 cell expressing BRAF V600E mutation. … (full text at CIViC)

PMID 26996308 · Foster et al., 2016 · Open in CIViC

In a case report, a patient with pancreatic cancer harboring BRAF N486-P490del was treated with trametinib. Within 4 weeks of initiating therapy, her serum CA19-9 had fallen from 36,000 to 8,100 U/mL,… (full text at CIViC)

PMID 29903880 · Aguirre et al., 2018 · Open in CIViC

Eight patients with BRAF V600 (7 with V600E, 1 with V600 unknown) mutated cholangiocarcinoma received vemurafenib. Only one patients showed partial response and duration of response of this patient wa… (full text at CIViC)

PMID 26287849 · Hyman et al., 2015 · Open in CIViC

In NCI-MATCH trial, patients with advanced solid tumors, lymphoma or multiple myeloma harboring BRAF V600E mutation were treated with dabrafenib and trametinib. Patients with melanoma, thyroid carcino… (full text at CIViC)

Open in CIViC

Chemotherapy-refractory, metastatic cholangiocarcinoma with CNS involvement and a BRAF V600E mutation had a partial response at 8 weeks to dabrafenib and trametinib combination with complete radiologi… (full text at CIViC)

PMID 28480077 · Kocsis et al., 2017 · Open in CIViC

In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (74 y/F) with pancreatic cancer harboring, BRAF V600E, SMAD4 Loss, ERBB2 amplification, and, TP53 V… (full text at CIViC)

PMID 36670111 · Shaya et al., 2023 · Open in CIViC

In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to ma… (full text at CIViC)

PMID 31157963 · Golan et al., 2019 · Open in CIViC

In multicenter phase II study included individuals with a germline BRCA1/2 mutation and pancreatic cancer after gemcitabine treatment. Olaparib was administered at 400 mg twice per day. Tumor respons… (full text at CIViC)

PMID 25366685 · Kaufman et al., 2015 · Open in CIViC

Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=2… (full text at CIViC)

PMID 25072261 · Golan et al., 2014 · Open in CIViC

Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Five (21.7%) patients had a BRCA1 mutation. All but one had received prior gemcitabine, and 65% had … (full text at CIViC)

PMID 25366685 · Kaufman et al., 2015 · Open in CIViC

In this phase II study, 46 patients were enrolled (42 were evaluable; 27 gBRCA2, seven gBRCA1, six gPALB2, and two sBRCA2) and their chemotherapy was discontinued; patients then received rucaparib 600… (full text at CIViC)

PMID 33970687 · Reiss et al., 2021 · Open in CIViC

In pancreatic cell lines PL11 (FANCC-deficient) and CAPAN1 (BRCA2-mutated), sensitivity to DNA cross-linking agents was observed compared to FANCC/BRCA2 wildtype cell lines (Su86.86, CFPAC, AsPc1, and… (full text at CIViC)

PMID 16243825 · van der Heijden et al., 2005 · Open in CIViC

In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to ma… (full text at CIViC)

PMID 31157963 · Golan et al., 2019 · Open in CIViC

Patient with germline BRCA2 mutation underwent resection of pancreatic cancer. Around three years later, tumor recurrence was detected by MRI and PET-CT confirmed it. She was treated with gemcitabine … (full text at CIViC)

PMID 21508395 · Fogelman et al., 2011 · Open in CIViC

Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation. In total of patients with BRCA1/2 mutation , all but … (full text at CIViC)

PMID 25366685 · Kaufman et al., 2015 · Open in CIViC

In a multivariate analysis from a clinical trial of 101 patients, CD44v6 expression combined with CD44s non-expression is significantly correlated with a reduced survival (p= 0.003).

PMID 24708709 · Li et al., 2014 · Open in CIViC

A phase II clinical study conducted with 12 patients with pancreatic cancer with CDKN2A loss or mutation treated with palbociclib. No clinical activity demonstrated in patients with CDKN2A mutated/del… (full text at CIViC)

PMID 35100714 · Al Baghdadi et al., 2019 · Open in CIViC

In a phase 2 trial, patients with pancreatic cancer with CDKN2A loss or mutation were received palbociclib. Among 12 patients no overall response or stable disease at 16 weeks were observed.

Open in CIViC

In a phase 2 trial, patients with gallbladder cancer or bile duct cancer with CDKN2A loss or mutation were received palbociclib. Among 10 patients, no overall response or stable disease at 16 weeks we… (full text at CIViC)

Open in CIViC

A 35 year-old patient presented with a grade 3 pancreatic neuroendocrine tumor and liver metastasis. Whole genome sequencing and RNAseq revealed a previously undescribed somatic translocation between … (full text at CIViC)

PMID 31160355 · Williamson et al., 2019 · Open in CIViC

CIC knockout conferred resistance to selumetinib in KRAS G12V (PATU8902) pancreatic cancer cells.

PMID 28178529 · Wang et al., 2017 · Open in CIViC

In a CRISPR-Cas9 screen in two KRAS G12V pancreatic cancer cell lines (PATU8902, PATU8988T), CIC was found to promote proliferation/survival in the context of trametinib treatment. Additional in vitro… (full text at CIViC)

PMID 28178529 · Wang et al., 2017 · Open in CIViC

Expression of the protein CIP2A was investigated in 72 cases of pancreatic ductal adenocarcinoma and 27 cases of adjacent tissues. Immunohistochemistry revealed a significant difference in expression … (full text at CIViC)

PMID 26894380 · Xu et al., 2016 · Open in CIViC

Researchers studied the effect of CIP2A expression in relation to gemcitabine sensitivity via SW1990 cell lines. SW1990 cells with CIP2A expression knocked-down displayed lower IC50 (p=.024), indicat… (full text at CIViC)

PMID 26894380 · Xu et al., 2016 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One of 23 pa… (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

Patients with recurrent pancreatic adenocarcinoma was treated with gemcitabine + nab-paclitaxel, FOLFIRINOX and docetaxel + irinotecan. After failure of these treatment, a tumor specimen from the panc… (full text at CIViC)

PMID 28874593 · Cecchini et al., 2017 · Open in CIViC

In a study of 137 biliary tract carcinomas, 13 patients were identified to have EGFR variants in exons 18-21 (no other exons were evaluated). EGFR variants were associated with worse survival in univa… (full text at CIViC)

PMID 24372748 · Chang et al., 2014 · Open in CIViC